QHSLab (USAQ) 10-K 27 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 26, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	0-19041
Entity Registrant Name	QHSLab, Inc.
Entity Central Index Key	0000856984
Entity Tax Identification Number	30-1104301
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	901 Northpoint Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, Address Line Three	West Palm
Entity Address, City or Town	Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33407
City Area Code	(929)
Local Phone Number	379-6503
Title of 12(b) Security	Common Stock, $0.0001 Par Value
Trading Symbol	USAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 882,578
Entity Common Stock, Shares Outstanding		10,215,508
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Name	Accell Audit & Compliance, P.A.
Auditor Firm ID	3289
Auditor Location	Tampa, Florida

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 51,582	$ 178,694
Accounts receivable, net	71,382	47,734
Inventory	25,181	51,840
Prepaid expenses and other current assets	7,987	7,310
Total current assets	156,132	285,578
Non-current assets:
Capitalized software development costs, net	93,079	167,543
Intangible assets, net	1,432,221	1,504,332
Total assets	1,681,432	1,957,453
Current Liabilities:
Accounts payable	78,907	85,743
Other current liabilities	196,590	116,774
Loans payable, current portion	546,052	342,391
Convertible notes payable	1,235,500	1,161,918
Total current liabilities	2,057,049	1,706,826
Non-current liabilities:
Loans payable, non-current portion		174,382
Total non-current liabilities		174,382
Total liabilities	2,057,049	1,881,208
Stockholders’ (Deficit) Equity:
Common stock, 900,000,000 shares authorized, $0.0001 par value; 9,735,508 and 9,315,508 shares issued and outstanding at December 31, 2023 and 2022, respectively	974	932
Additional paid-in capital	3,606,295	3,589,837
Accumulated deficit	(3,983,258)	(3,514,896)
Total stockholders’ (deficit) equity	(375,617)	76,245
Total liabilities and stockholders’ (deficit) equity	1,681,432	1,957,453
Series A Preferred Stock [Member]
Stockholders’ (Deficit) Equity:
Preferred stock	108	108
Series A Two Preferred Stock [Member]
Stockholders’ (Deficit) Equity:
Preferred stock	$ 264	$ 264

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.25
Common Stock, Shares Authorized		900,000,000
Common Stock, Par or Stated Value Per Share		$ 0.0001
Common stock, shares issued	9,735,508	9,315,508
Common stock, shares outstanding	9,735,508	9,315,508
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	1,080,092	1,080,092
Preferred stock, shares outstanding	1,080,092	1,080,092
Series A Two Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	2,644,424	2,644,424
Preferred stock, shares outstanding	2,644,424	2,644,424

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 1,408,995	$ 1,243,186
Cost of revenue	615,388	623,667
Gross profit	793,607	619,519
Operating Expenses:
Sales and marketing	488,537	530,317
General and administrative	259,108	387,512
Research and development	214,008	190,117
Amortization	72,112	72,112
Total Operating Expenses	1,033,765	1,180,058
Net operating loss	(240,158)	(560,539)
Other income (expense)
Interest expense	(230,494)	(433,442)
Other income	2,290
Loss on extinguishment of debt		(2,020)
Loss before income taxes	(468,362)	(996,001)
Provision on income taxes
Net loss	$ (468,362)	$ (996,001)
Basic net loss per share	$ (0.05)	$ (0.11)
Diluted net loss per share	$ (0.05)	$ (0.11)
Weighted average shares outstanding: (Basic)	9,416,768	8,997,129
Weighted average shares outstanding: (Diluted)	9,416,768	8,997,129

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Two Preferred Stock [Member]	Common Stock [Member]	Unearned Stock Compensation (Member)	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 108	$ 264	$ 876	$ (6,968)	$ 3,348,681	$ (2,518,895)	$ 824,066
Balance, shares at Dec. 31, 2021	1,080,092	2,644,424	8,756,093
Warrants issued as deferred financing costs					81,183		81,183
Shares issued for services				6,968			6,968
Conversion of notes payable			$ 31		77,894		77,925
Conversion of notes payable, shares			309,415
Warrants issued with conversion of notes payable					2,020		2,020
Stock-based compensation expense					30,084		30,084
Share purchase			$ 25		49,975		50,000
Share purchase, shares			250,000
Net loss						(996,001)	(996,001)
Balance at Dec. 31, 2022	$ 108	$ 264	$ 932		3,589,837	(3,514,896)	76,245
Balance, shares at Dec. 31, 2022	1,080,092	2,644,424	9,315,508
Conversion of notes payable			$ 42		10,458		10,500
Conversion of notes payable, shares			420,000
Stock-based compensation expense					6,000		6,000
Net loss						(468,362)	(468,362)
Balance at Dec. 31, 2023	$ 108	$ 264	$ 974		$ 3,606,295	$ (3,983,258)	$ (375,617)
Balance, shares at Dec. 31, 2023	1,080,092	2,644,424	9,735,508

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating activities
Net loss	$ (468,362)	$ (996,001)
Adjustments to reconcile net loss to net cash from operating activities:
Allowance for doubtful accounts	10,216	8,230
Amortization	146,575	127,959
Amortization of debt and warrant issuance costs	84,082	305,996
Stock-based compensation	6,000	30,084
Shares issued for services		6,968
Loss on extinguishment of debt		2,020
Changes in operating assets and liabilities:
Accounts receivable	(33,864)	14,510
Inventory	26,659	13,900
Prepaid expenses and other current assets	(677)	15,403
Accounts payable	(6,836)	65,374
Other current liabilities	76,580	54,563
Cash flows from operating activities	(159,627)	(350,994)
Investing activities:
Capitalized software		(37,119)
Cash flows from investing activities		(37,119)
Financing activities:
Proceeds from sales of common stock		50,000
Issuance of convertible notes payable		400,000
Proceeds from related-party borrowings	3,236
Proceeds of loan borrowings	388,700	239,800
Repayments of loan borrowings	(359,421)	(379,848)
Payment of debt issuance costs		(30,000)
Cash flows from financing activities	32,515	279,952
Change in cash	(127,112)	(108,161)
Cash and cash equivalents - beginning of year	178,694	286,855
Cash and cash equivalents - end of period	51,582	178,694
Supplemental disclosures of cash flow activity:
Cash paid for interest	61,295	71,785
Cash paid for taxes
Supplemental noncash investing and financing activity:
Debt and accrued interest converted to shares of common stock	10,500	77,925
Warrants issued in conjunction with convertible note payable		$ 81,183

The Company

The Company	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1. The Company QHSLab, Inc. (the “Company” or the “Registrant”) was incorporated in Delaware on September 1, 1983. In 2019, the Company became engaged in value-based healthcare, informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. On September 23, 2021, the Company changed its state of incorporation from Delaware to Nevada. On April 19, 2022, the Company changed its name to QHSLab, Inc. The Company is a medical device technology and software-as-a-service (“SaaS”) company focused on enabling primary care physicians (“PCP’s”) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception and continues to have negative operating cash flows. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company’s business is dependent upon its ability to achieve profitability and positive cash flows and, pending such achievement, future issuances of equity or other financings to fund ongoing operations. However, access to such funding may not be available on commercially reasonable terms, if at all. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Note 3. Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). In the opinion of management, the accompanying audited consolidated financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. Accounting Policies Use of Estimates Principles of Consolidation Cash and Cash Equivalents Accounts Receivable 12.3 10.4 Inventories Capitalized Software Development Costs Internal-Use Software The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software totaled $ 93,079 167,543 74,464 55,847 no Intangible Assets Business Combination, Related Issues, Initial Measurement Intangibles, General Intangibles Other Than Goodwill Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances occur which may result in an impact to the value of the assets. Convertible Notes Payable : The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity Revenue Recognition Revenue from Contracts with Customers, To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. The Company includes shipping and handling fees billed to customers in revenue. The Company also generates revenue through Software-as-a-Service (SaaS) agreements whereby the Company provides physicians’ practices access to its proprietary internally-developed software that provides clinical decision support and patient monitoring. The agreements provide for either monthly or annual access to the software. The access to the system begins immediately and revenue is recognized over the agreement term. The Company provides administrative, billing and support services utilizing the Company’s internally-developed software. Revenue is recognized each month based on actual services provided during that month. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract. Research and Development 214,008 190,117 Stock-based Compensation Share Based Payment Earnings Per Common Share Income Taxes Income Taxes, The Company has net operating losses of $ 3,983,258 begin to expire in 2027 Recently Issued Accounting Standards I Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This Annual Report on Form 10-K does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2023
Credit Loss [Abstract]
Accounts Receivable	Note 4. Accounts Receivable Accounts receivable is recorded in the consolidated balance sheets when customers are invoiced for revenue to be collected and there is an unconditional right to receive payment. Timing of revenue recognition may differ from the timing of invoicing customers resulting in deferred revenue until the Company satisfies its performance obligation. Accounts receivable is presented net of an allowance for doubtful accounts that represents future expected credit losses over the life of the receivables based on past experience, current information and forward-looking economic considerations. The beginning and ending balances of accounts receivable, net of allowance, are as follows: Schedule of Accounts Receivable December 31, December 31, Accounts receivable $ 89,827 $ 55,964 Allowance for doubtful accounts (18,445 ) (8,230 ) Accounts receivable, net $ 71,382 $ 47,734

Capitalized Software and Intang

Capitalized Software and Intangible Assets	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Capitalized Software and Intangible Assets	Note 5. Capitalized Software and Intangible Assets Non-current assets consist of the following at December 31, 2023 and 2022: Schedule of Intangible Assets Estimated Useful Life December 31, 2023 December 31, 2022 Capitalized software 3.0 $ 223,390 $ 223,390 Accumulated amortization (130,311 ) (55,847 ) Capitalized software, net $ 93,079 $ 167,543 Intangible Assets: U.S. Method Patent 13.4 $ 967,500 $ 967,500 Web Domain N/A 161,250 161,250 Trademark N/A 483,750 483,750 Total Intangible assets $ 1,612,500 $ 1,612,500 Accumulated amortization (180,279 ) (108,168 ) Intangible assets, net $ 1,432,221 $ 1,504,332 Capitalized software represents the development costs for the Company’s internal-use QHSLab platform software. The Company completed testing of its QHSLab platform software application at the end of the first quarter of 2022 and began to amortize the capitalized expenses on a straight-line basis over the useful life of the software. During the years ended December 31, 2023 and 2022 there was $ 74,464 55,847 no The intangible assets represent the value the Company paid to acquire the trademark “AllergiEnd”, the web domain “AllergiEnd.com” along with the U.S. Method Patent registration relating to the allergy testing kit and related materials the Company distributes to physician clients. The Company acquired the intangible assets from MedScience Research Group as of June 23, 2021 for total consideration of $ 1,612,500 Business Combination, Related Issues, Initial Measurement. Intangibles, General Intangibles Other Than Goodwill 72,112 The Company evaluates intangible assets with infinite lives for impairment at least annually and evaluates intangible assets with finite lives when events or circumstances indicate an impairment may exist. No impairments or changes in useful lives were recognized during the years ended December 31, 2023 and 2022.

Loans Payable

Loans Payable	12 Months Ended
	Dec. 31, 2023
Loans Payable
Loans Payable	Note 6. Loans Payable On June 23, 2021, the Company entered into a purchase agreement to acquire certain assets from MedScience Research Group, Inc (“MedScience”) (See Note 5 for additional information). As part of that purchase agreement, the Company issued a Promissory Note with a principal sum of $ 750,000 396,138 426,451 On November 28, 2022, the Company entered into another fixed-fee short-term loan with its merchant bank and received $ 111,300 May 2024 13,776 0 93,146 On April 21, 2023, the Company entered into a fixed-fee short-term loan with its merchant bank and received $ 162,000 20,538 October 2024 On October 5, 2023, the Company entered into a fixed-fee short-term loan with its merchant bank and received $ 226,700 28,463 174,092

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 7. Convertible Notes Payable Convertible notes payable at December 31, 2023 and 2022 consist of the following: Schedule of Convertible Notes Payable December 31, December 31, Note 1 – Shareholder $ 100,000 $ 100,000 Note 2 – Mercer Note 695,500 706,000 Note 3 – Mercer Note #2 440,000 440,000 Total 1,235,500 1,246,000 Debt discount and issuance costs - (84,082 ) Total convertible notes payable 1,235,500 1,161,918 Less: current portion 1,235,500 1,161,918 Non-current portion $ - $ - Note 1 – Effective May 7, 2021, the Company issued a Convertible Promissory Note in the principal amount of $ 100,000 10 September 30, 2022 The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of common shares at a conversion price equal to the greater of a 25% discount to the 15-day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time through the maturity date of December 31, 2023 at the option of the holder using the same conversion calculation 26,521 16,521 Note 2 – Effective August 10, 2021, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which it issued to the investor an Original Issue Discount Secured Convertible Promissory Note (the “$806,000 Note”) in the principal amount of $ 806,000 930,000 750,000 The principal amount of the $ 806,000 806,000 5 0.65 806,000 806,000 On November 11, 2021, Mercer Street Global Opportunity Fund, LLC (“Mercer Fund”), converted $ 50,000 806,000 76,923 0.65 The 930,000 three years 1.25 806,000 As a result of the issuance of a $ 440,000 0.20 806,000 0.20 50,000 806,000 250,000 0.20 On October 5, 2023, at the request of Mercer Fund, the Company agreed to reduce the conversion price with respect to $ 10,500 806,000 0.025 806,000 0.20 On February 19, 2024, the Company received the most recent notice from the manager of Mercer Fund of its agreement to forebear from the exercise of any rights it might have as a result of any defaults under the $ 806,000 806,000 5 As of December 31, 2023, all original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, have been recognized. The remaining principal balance of $ 695,500 , along with associated interest, is recorded with current liabilities on the Company’s consolidated balance sheets. As of December 31, 2023, the $ 806,000 Note had $ 87,344 of accrued interest, total unamortized debt issuance costs of $ 0 , including the Warrant and the remaining discount. As of December 31, 2022, the $ 806,000 Note had $ 52,171 of accrued interest. Note 3 – Effective July 19, 2022, the Company entered into a Securities Purchase Agreement with Mercer Fund pursuant to which it issued an Original Issue Discount Secured Convertible Promissory Note (the “$440,000 Note”) in the principal amount of $ 440,000 550,000 400,000 The principal amount of the $ 440,000 440,000 5 0.20 440,000 440,000 The $ 440,000 440,000 440,000 440,000 440,000 On February 19, 2024 the Company received the most recent notice from the manager of the Mercer Fund, LLC that it agreed to forebear from exercising any rights it might have as a result of any defaults under the $ 440,000 The 550,000 0.50 440,000 The Registration Rights Agreement requires the Company to file with the Securities and Exchange Commission within 60 days following the closing of the issuance of the $ 440,000 440,000 440,000 The Company accounts for the allocation of its issuance costs related to its Warrants in accordance with ASC 470-20, Debt with Conversion and Other Options The Company estimated the fair value of the Warrants utilizing the Black-Scholes pricing model, which is dependent upon several assumptions such as the expected term of the Warrants, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected term and expected dividend yield rate over the expected term. The Company believes this valuation methodology is appropriate for estimating the fair value of warrants. The value allocated to the relative fair value of the Warrants was recorded as debt issuance costs and additional paid in capital. The principal, net of the original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, which are being recognized over the life of the $ 440,000 440,000 31,764 0 440,000 9,764 61,836 22,247

Preferred Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Preferred Stock	Note 8. Preferred Stock Issuance of Series A Preferred Stock The shares of Series A Preferred Stock have a stated value of $ 0.25 0.05 Issuance of Series A-2 Preferred Stock The shares of Series A-2 Preferred Stock have a stated value of $ 0.16 0.16 Holders of the Series A-2 Convertible Preferred Stock will vote on an as converted basis with the holders of the Company’s common stock and Series A Preferred Shares as to all matters to be voted on by the holders of the common stock. Each Series A-2 Preferred Share shall be entitled to a number of votes equal to five times the number of shares of common stock into which it is then convertible on the applicable record date.

Loss Per Common Share

Loss Per Common Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Loss Per Common Share	Note 9. Loss Per Common Share The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share Schedule of Anti-dilutive Securities Excluded from Calculation of Earning Per Share 2023 2022 Years Ended 2023 2022 Stock options 1,100,000 1,100,000 Stock warrants 1,494,854 1,576,647 Total shares excluded from calculation 2,594,854 2,676,647 Antidilutive securities 2,594,854 2,676,647

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Note 10. Stock-based Compensation During the years ended December 31, 2023 and 2022, there was $ 6,000 30,084 0 6,968 There were no options granted during the years ended December 31, 2023 and 2022. There were no options exercised, forfeited or cancelled during either period. As of December 31, 2023, all compensation related to the 1,100,000 6,000 1,100,000 3 Options outstanding at December 31, 2023 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date March 12, 2020 500,000 500,000 $ 0.40 March 12, 2025 June 27, 2020 150,000 150,000 $ 0.40 June 27, 2025 January 1, 2021 450,000 450,000 $ 0.65 December 31, 2025 Total 1,100,000 1,100,000 Warrants outstanding at December 31, 2023 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 February 23, 2022 14,854 14,854 $ 0.705 February 22, 2024 July 19, 2022 550,000 550,000 $ 0.50 July 18, 2025 Total 1,494,854 1,494,854

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related-Party Transactions	Note 11. Related-Party Transactions Due to Related Parties: 3,236 0 Convertible notes payable, related party:

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 12. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, The valuation allowance at December 31, 2023 and 2022 was $ 836,484 738,128 98,356 209,160 Reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for 2023 and 2022 are as follows: Schedule of Effective Income Tax Reconcillation 2023 2022 For the Years Ended December 31, 2023 2022 Income tax at federal statutory rate 21.00 % 21.00 % Valuation allowance (21.00 )% (21.00 )% Income tax expense — — The Company has net operating losses of $ 3,983,258 begin to expire in 2027

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13. Commitments and Contingencies There are no pending or threatened legal proceedings as of December 31, 2023. The Company has no non-cancellable operating leases.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Event	Note 14. Subsequent Event On March 4, 2024, Mercer Street Global Opportunity Fund, LLC, converted $ 10,500 806,000 420,000 0.025

Basis of Presentation (Policies

Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates
Principles of Consolidation	Principles of Consolidation
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable 12.3 10.4
Inventories	Inventories
Capitalized Software Development Costs	Capitalized Software Development Costs Internal-Use Software The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software totaled $ 93,079 167,543 74,464 55,847 no
Intangible Assets	Intangible Assets Business Combination, Related Issues, Initial Measurement Intangibles, General Intangibles Other Than Goodwill Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances occur which may result in an impact to the value of the assets.
Convertible Notes Payable	Convertible Notes Payable : The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
Revenue Recognition	Revenue Recognition Revenue from Contracts with Customers, To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. The Company includes shipping and handling fees billed to customers in revenue. The Company also generates revenue through Software-as-a-Service (SaaS) agreements whereby the Company provides physicians’ practices access to its proprietary internally-developed software that provides clinical decision support and patient monitoring. The agreements provide for either monthly or annual access to the software. The access to the system begins immediately and revenue is recognized over the agreement term. The Company provides administrative, billing and support services utilizing the Company’s internally-developed software. Revenue is recognized each month based on actual services provided during that month. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract.
Research and Development	Research and Development 214,008 190,117
Stock-based Compensation	Stock-based Compensation Share Based Payment
Earnings Per Common Share	Earnings Per Common Share
Income Taxes	Income Taxes Income Taxes, The Company has net operating losses of $ 3,983,258 begin to expire in 2027
Recently Issued Accounting Standards	Recently Issued Accounting Standards I Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This Annual Report on Form 10-K does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Indefinite-Lived Intangible Assets	Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life

Accounts Receivable (Tables)

Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2023
Credit Loss [Abstract]
Schedule of Accounts Receivable	Schedule of Accounts Receivable December 31, December 31, Accounts receivable $ 89,827 $ 55,964 Allowance for doubtful accounts (18,445 ) (8,230 ) Accounts receivable, net $ 71,382 $ 47,734

Capitalized Software and Inta_2

Capitalized Software and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Non-current assets consist of the following at December 31, 2023 and 2022: Schedule of Intangible Assets Estimated Useful Life December 31, 2023 December 31, 2022 Capitalized software 3.0 $ 223,390 $ 223,390 Accumulated amortization (130,311 ) (55,847 ) Capitalized software, net $ 93,079 $ 167,543 Intangible Assets: U.S. Method Patent 13.4 $ 967,500 $ 967,500 Web Domain N/A 161,250 161,250 Trademark N/A 483,750 483,750 Total Intangible assets $ 1,612,500 $ 1,612,500 Accumulated amortization (180,279 ) (108,168 ) Intangible assets, net $ 1,432,221 $ 1,504,332

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable at December 31, 2023 and 2022 consist of the following: Schedule of Convertible Notes Payable December 31, December 31, Note 1 – Shareholder $ 100,000 $ 100,000 Note 2 – Mercer Note 695,500 706,000 Note 3 – Mercer Note #2 440,000 440,000 Total 1,235,500 1,246,000 Debt discount and issuance costs - (84,082 ) Total convertible notes payable 1,235,500 1,161,918 Less: current portion 1,235,500 1,161,918 Non-current portion $ - $ -

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Securities Excluded from Calculation of Earning Per Share	Schedule of Anti-dilutive Securities Excluded from Calculation of Earning Per Share 2023 2022 Years Ended 2023 2022 Stock options 1,100,000 1,100,000 Stock warrants 1,494,854 1,576,647 Total shares excluded from calculation 2,594,854 2,676,647 Antidilutive securities 2,594,854 2,676,647

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Options Outstanding and Exercisable	Options outstanding at December 31, 2023 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date March 12, 2020 500,000 500,000 $ 0.40 March 12, 2025 June 27, 2020 150,000 150,000 $ 0.40 June 27, 2025 January 1, 2021 450,000 450,000 $ 0.65 December 31, 2025 Total 1,100,000 1,100,000
Schedule of Warrants Outstanding and Exercisable	Warrants outstanding at December 31, 2023 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 February 23, 2022 14,854 14,854 $ 0.705 February 22, 2024 July 19, 2022 550,000 550,000 $ 0.50 July 18, 2025 Total 1,494,854 1,494,854

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Reconcillation	Reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for 2023 and 2022 are as follows: Schedule of Effective Income Tax Reconcillation 2023 2022 For the Years Ended December 31, 2023 2022 Income tax at federal statutory rate 21.00 % 21.00 % Valuation allowance (21.00 )% (21.00 )% Income tax expense — —

Schedule of Indefinite-Lived In

Schedule of Indefinite-Lived Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2023
Web Domain [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired intangible asset	Indefinite life
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired intangible asset	Indefinite life
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	13 years 4 months 24 days

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Product Information [Line Items]
Capitalized software development costs	$ 93,079	$ 167,543
Amortization recognized	74,464	55,847
Impairments recognized	0	0
Research and development expense	214,008	$ 190,117
Operating loss carryforwards	$ 3,983,258
Net operating losses carryforwards, expire date	begin to expire in 2027
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration risk percentage	12.30%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage	10.40%

Schedule of Accounts Receivable

Schedule of Accounts Receivable (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Credit Loss [Abstract]
Accounts receivable	$ 89,827	$ 55,964
Allowance for doubtful accounts	(18,445)	(8,230)
Accounts receivable, net	$ 71,382	$ 47,734

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Capitalized software	$ 223,390	$ 223,390
Accumulated amortization	(130,311)	(55,847)
Capitalized software, net	93,079	167,543
Intangible Assets:
Total Intangible assets	1,612,500	1,612,500
Accumulated amortization	(180,279)	(108,168)
Intangible assets, net	$ 1,432,221	1,504,332
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	3 years
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	13 years 4 months 24 days
Intangible Assets:
Total Intangible assets	$ 967,500	967,500
Web Domain [Member]
Intangible Assets:
Total Intangible assets	161,250	161,250
Trademarks [Member]
Intangible Assets:
Total Intangible assets	$ 483,750	$ 483,750

Capitalized Software and Inta_3

Capitalized Software and Intangible Assets (Details Narrative) - USD ($)		12 Months Ended
	Jun. 23, 2021	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization recognized		$ 74,464	$ 55,847
Impairments recognized		0	0
Acquired intangible assets	$ 1,612,500
Amortization		$ 72,112	$ 72,112

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) - USD ($)	Oct. 05, 2023	Apr. 21, 2023	Nov. 28, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 23, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt default long term debt amount				$ 396,138	$ 426,451
Proceeds from loan	$ 226,700	$ 162,000	$ 111,300
Loan payable maturity date		October 2024	May 2024
Payments for loan	$ 28,463	$ 20,538	$ 13,776
Loan payable				0	$ 93,146
Loan payable				$ 174,092
Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument face amount						$ 750,000

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2023	Aug. 10, 2023	Jul. 19, 2023	Dec. 31, 2022	Aug. 10, 2022
Short-Term Debt [Line Items]
Total	$ 1,235,500			$ 1,246,000
Debt discount and issuance costs				(84,082)
Total convertible notes payable	1,235,500			1,161,918
Less: current portion	1,235,500			1,161,918
Non-current portion
Convertible Notes Payable One [Member] | Note 1 – Shareholder [Member]
Short-Term Debt [Line Items]
Total	100,000			100,000
Convertible Notes Payable Two [Member] | Note 2 – Mercer Note [Member]
Short-Term Debt [Line Items]
Total	695,500			706,000
Convertible Notes Payable Three [Member] | Note 3 – Mercer Note #2 [Member]
Short-Term Debt [Line Items]
Total	440,000			440,000
Total convertible notes payable	$ 440,000	$ 806,000	$ 440,000	$ 440,000	$ 806,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)									12 Months Ended
	Mar. 04, 2024	Feb. 19, 2024	Oct. 05, 2023	Jul. 27, 2022	Jul. 19, 2022	Nov. 11, 2021	Aug. 10, 2021	May 07, 2021	Dec. 31, 2023	Dec. 31, 2022	Aug. 10, 2023	Jul. 19, 2023	Aug. 10, 2022
Short-Term Debt [Line Items]
Convertible notes payable									$ 1,235,500	$ 1,161,918
Debt instrument convertible conversion price per share			$ 0.025				$ 0.025
Conversion of notes payable									10,500	77,925
Increase decrease in conversion price			$ 10,500
Conversion price			$ 806,000				$ 420,000
Conversion per share price			$ 0.20
Subsequent Event [Member]
Short-Term Debt [Line Items]
Increase decrease in conversion price	$ 10,500
Conversion price	$ 806,000
Exercise value		$ 440,000
Note 2 – Mercer Note [Member] | Securities Purchase Agreement [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount						$ 806,000
Note 2 – Mercer Note [Member] | Securities Purchase Agreement [Member] | Mercer Street Global Opportunity Fund LLC [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount		806,000
Eight Hundred Six Thousand Note [Member] | Securities Purchase Agreement [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument convertible conversion price per share						$ 0.65
Conversion of notes payable						$ 50,000
Conversion of notes payable, shares						76,923
Convertible Notes Payable One [Member] | Note 1 – Shareholder [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount								$ 100,000
Debt instrument interest rate stated percentage								10%
Debt instrument, maturity date								Sep. 30, 2022
Debt instrument, description								The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of common shares at a conversion price equal to the greater of a 25% discount to the 15-day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time through the maturity date of December 31, 2023 at the option of the holder using the same conversion calculation
Interest payable, current									26,521	16,521
Convertible Notes Payable Three [Member] | Note 2 – Mercer Note [Member] | Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount				$ 806,000			$ 806,000		806,000	806,000
Number of securities called by warrants or rights						930,000	930,000
Proceeds from warrant exercises							$ 750,000
Warrants term						3 years
Exercise price of warrants or rights						$ 1.25
Convertible Notes Payable Three [Member] | Note 2 – Mercer Note [Member] | Securities Purchase Agreement [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount		$ 806,000
Debt instrument interest rate stated percentage		5%
Convertible Notes Payable Three [Member] | Note 2 – Mercer Note [Member] | Securities Purchase Agreement [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount				$ 50,000					695,500
Interest payable, current									87,344	52,171
Debt instrument convertible conversion price per share				$ 0.20
Conversion of notes payable, shares				250,000
Unamortized Debt Issuance Expense									0
Convertible Notes Payable Three [Member] | Note 3 – Mercer Note #2 [Member]
Short-Term Debt [Line Items]
Convertible notes payable									440,000	440,000	$ 806,000	$ 440,000	$ 806,000
Convertible Notes Payable Three [Member] | Note 3 – Mercer Note #2 [Member] | Securities Purchase Agreement [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Interest payable, current										9,764
Convertible Notes Payable Four [Member] | Note 3 – Mercer Note #2 [Member] | Securities Purchase Agreement [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount					$ 440,000
Debt instrument interest rate stated percentage					5%								5%
Interest payable, current									31,764
Proceeds from warrant exercises					$ 400,000
Debt instrument convertible conversion price per share					$ 0.20								$ 0.65
Exercise price of warrants or rights					$ 0.50
Warrants issued to purchase of common stock					550,000
Total unamortized debt issuance costs									$ 0	61,836
Remaining debt discount										$ 22,247
Convertible Notes Payable [Member] | Note 2 – Mercer Note [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount						$ 806,000

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - $ / shares	Dec. 30, 2021	Dec. 31, 2023	Oct. 05, 2023	Dec. 31, 2022	Aug. 10, 2021
Class of Stock [Line Items]
Preferred stock stated value		$ 0.25
Debt instrument convertible conversion price per share			$ 0.025		$ 0.025
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock stated value		0.0001		$ 0.0001
Debt instrument convertible conversion price per share		$ 0.05
Series A-2 Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stok stated value	$ 0.16
Number of shares convertible into common stock price per share	$ 0.16

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Calculation of Earning Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	2,594,854	2,676,647
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,100,000	1,100,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,494,854	1,576,647

Schedule of Options Outstanding

Schedule of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding	1,100,000
Option One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Mar. 12, 2020
Number Outstanding	500,000
Number Exercisable	500,000
Exercise Price | $ / shares	$ 0.40
Expiration Date	Mar. 12, 2025
Option Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jun. 27, 2020
Number Outstanding	150,000
Number Exercisable	150,000
Exercise Price | $ / shares	$ 0.40
Expiration Date	Jun. 27, 2025
Option Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jan. 01, 2021
Number Outstanding	450,000
Number Exercisable	450,000
Exercise Price | $ / shares	$ 0.65
Expiration Date	Dec. 31, 2025
Options Held [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding	1,100,000
Number Exercisable	1,100,000

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Warrant One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Aug. 10, 2021
Number Outstanding	930,000
Number Exercisable	930,000
Exercise Price | $ / shares	$ 1.25
Expiration Date	Aug. 09, 2024
Warrant Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Feb. 23, 2022
Number Outstanding	14,854
Number Exercisable	14,854
Exercise Price | $ / shares	$ 0.705
Expiration Date	Feb. 22, 2024
Warrant Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jul. 19, 2022
Number Outstanding	550,000
Number Exercisable	550,000
Exercise Price | $ / shares	$ 0.50
Expiration Date	Jul. 18, 2025
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding	1,494,854
Number Exercisable	1,494,854

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock based compensation	$ 6,000	$ 30,084
Allocated share based compensation expense	$ 0	$ 6,968
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross		0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period		0
Outstanding options, shares	1,100,000
Unrecognized compensation related to unvested options		$ 6,000
Unrecognized compensation related to unvested options, shares		1,100,000
Recognized weighted-average period	3 months

Related-Party Transactions (Det

Related-Party Transactions (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Amount due to related parties	$ 196,590	$ 116,774
Related Party [Member]
Related Party Transaction [Line Items]
Amount due to related parties	$ 3,236

Schedule of Effective Income Ta

Schedule of Effective Income Tax Reconcillation (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income tax at federal statutory rate	21%	21%
Valuation allowance	(21.00%)	(21.00%)
Income tax expense	0%	0%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Deferred tax assets, valuation allowance	$ 836,484	$ 738,128
Change in valuation allowance	98,356	$ 209,160
Operating losses carryforward	$ 3,983,258
Operating losses carryforward expiration date	begin to expire in 2027

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - USD ($)	Mar. 04, 2024	Oct. 05, 2023	Aug. 10, 2021
Subsequent Event [Line Items]
Increase decrease in conversion price		$ 10,500
Conversion price		$ 806,000	$ 420,000
Conversion per share price		$ 0.025	$ 0.025
Subsequent Event [Member]
Subsequent Event [Line Items]
Increase decrease in conversion price	$ 10,500
Conversion price	$ 806,000